Higher Entyvio serum levels linked to mucosal healing in Crohn’s

Patients with Crohn’s disease who had higher serum drug levels of Entyvio experienced better rates of endoscopic remission, according to study results published in Gastroenterology.
Geert D’Haens, MD, PhD, of the department of gastroenterology and hepatology at Amsterdam UMC, and colleagues sought to explore endoscopic histologic outcomes in patients with CD treated with Entyvio (vedolizumab, Takeda) for 52 weeks.
“Although the efficacy and safety of [vedolizumab] induction and maintenance therapy in CD has been confirmed in real life cohorts, only limited data are available

Source link

Related posts

Readmission for Patients With Sepsis Common and Costly


Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects


Huge Cancer Bill; Mixed Data for Vitamin D; Cancer's Toll on Function


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World